ISCPh: CLINICAL CANNABINOID PHARMACY 2020
AGENDA

 

THURSDAY, AUGUST 13, 2020

10 AM – 12 PM: General registration begins for tours – Please arrive before 15 min before scheduled departure time to ensure a timely departure. We don’t want to leave without you!  

1230 PM – 5 PM: Optional Accredited Tours; or view this content on-demand at home 

Examine the required components that make Cannabis medical

  1. Observe and organize the process to maintain pharmaceutical grade medicine
  2. Define potential contaminants during various stages of medical Cannabis production
  3. Determine the importance of genetic consistency or variability when creating pharmaceutical preparations
  4.  Summarize the role of the 2018 Farm Bill and the implications for hemp–based products
  5. Outline testing standards that ensure consistent and reliable products
  6. Evaluate the importance of traceability across the manufacturing process
  7. Explain the various analytical tools used to determine safety and potency
  8. Summarize operating procedures for safe handling of Cannabis products to prevent diversion
  9. Compare FDA recall classes to Cannabis industry recall practices
  10. Illustrate the need for HIPAA-compliant record keeping requirements in medical dispensaries
  11. Determine important counseling considerations when dispensing cannabinoid products
  12. Review product labeling to determine chemical composition, concentration, and calculate days supplied

 

5 PM – 9 PM: General registration

7 PM – 9 PM: Optional: Dinner with tour attendees and speakers 

 

FRIDAY, AUGUST 14, 2020

7 AM – 8 AM: Registration and Breakfast

745 AM – 9 AM: Endocannabinoids with Dr. Dustin Sulak, DO    

Discover the structure and function of the Endocannabinoid System (ECS)

  1. Identify the principle mediators of the ECS
  2. Examine the functions of the Endocannabinoid system (ECS)
  3. Explain the theory of Clinical Endocannabinoid Dysfunction (CECD)

 

9 AM – 945 AM: Phytocannabinoids with Dr. Linda Klumpers, PhD

Analyze the pharmacological and pharmacokinetic properties of major cannabinoids

  1. Compare the structure and function of major and minor cannabinoids including THC, CBD, CBN, CBG, CBC, and THCV
  2. Explore the role of the entourage hypothesis including the role of terpenes and flavonoids
  3. Summarize the pharmacodynamics effects of major and minor cannabinoids
  4. Examine the varying onset and duration of commonly available formulations

 

945 AM – 1015 AM: PK/PD Drug Interactions with Dr. Christine Roussel, PharmD, BCOP

Determine clinically relevant drug-drug and drug-disease interactions

  1. Summarize the CYP P450 pathways for major and minor cannabinoids
  2. Identify clinically relevant drug-drug and drug-disease interactions with cannabinoids; THC and CBD
  3. Recommend strategies to manage drug-drug and drug-disease interactions with medical Cannabis products

 

1015 AM – 1045 AM: Exhibitor Break  

1045 AM – 1145 AM: Cannabis in Cancer Care with Dr. Donald Abrams, MD  

Evaluate the use of Cannabis medicine in palliative care

  1. Identify potential uses of Cannabis medicine during Cancer care
  2. Review information regarding the use of Cannabis as an anti-cancer agent
  3. Discuss precautions that may avert Cannabis-associated harm

 

1145 AM – 1230 PM: Cannabis and Opioid Interactions with Dr. Dustin Sulak, DO      

Propose medical Cannabis as an alternative to opioids for pain management

  1. Discuss the overlap between the endogenous opioid and endocannabinoid systems
  2. Justify the use of cannabis products including THC and CBD in various pain models
  3. Examine dosing schedules that reduce opioid use to promote multimodal pain management

 

1230 PM – 1245 PM: Case Discussion #1: Palliative Care 

Design safe and effective palliative care regimens for complex patient presentations

  1. Explain potential disease-state interactions with cannabinoids and formulations
  2. Develop appropriate initial recommendations for cannabis-naïve and experienced patients

 

1245 PM – 145 PM: Lunch 

145 PM – 215 PM: Managing Cannabinoid Toxicity with Dr. Melani Kane, PharmD  

Review and resolve medication therapies for potential toxicity

  1. Define cannabinoid-specific and formulation-specific adverse reactions
  2. Outline potential strategies to mitigate cannabinoid medicine toxicity

 

215 PM – 3 PM:  Cannabis in Neurological Disorders with Dr. Stacia Woodcock, PharmD

Evaluate the role of phytocannabinoids in various degenerative and non-degenerative neurological disorders

  1. Summarize the literature surrounding medical cannabis in neurological disorders including; Multiple Sclerosis, Amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s disease, Tourette’s syndrome, Alzheimer’s, Autism, Epilepsy, Chronic Traumatic Encephalopathy (CTE), and PTSD
  2. Demonstrate the benefit versus risk of phytocannabinoids in various neurological disorders
  3. Relate the pharmacologic actions of phytocannabinoids to conventional therapies in neurological disorders

 

3 PM – 330 PM: Cannabis in GI Disorders with Mr. Brian Essenter, RPh       

Outline the role of cannabis medicine in gastrointestinal disorders

  1. Summarize the literature evaluating medical Cannabis in Crohn’s disease, ulcerative colitis, IBS, and liver disease
  2. Evaluate the use of common formulations in G/J tube

 

330 PM – 4 PM: Exhibitor Break  

4 PM – 430 PM: Cannabis in Immunology with Dr. Christine Roussel, PharmD, BCOP

Identify the intricate relationship between the ECS and the immune system

  1. Illustrate the role of the ECS in inflammatory conditions including psoriasis, solid organ transplant, bone marrow transplant, and rheumatoid arthritis
  2. Demonstrate the potential interaction between Cannabis products and immunomodulators

 

430 – 5 PM: Incorporating Hemp/Cannabidiol in Your Clinical Practice with TBD

Interpret the clinical role of hemp-based Cannabidiol in clinical practice 

  1. Identify medical conditions that could benefit from hemp extractions 
  2. Compare the advantages and disadvantages to available CBD formulations including isolates, broad-spectrum, and full-spectrum extractions
  3. Formulate a monitoring plan to determine safe and effective use of CBD

 

5 PM – 515 PM: Patient Consultations; Osteopathic Perspective with Dr. Dustin Sulak, DO 

Integrate medical Cannabis as a complementary or alternative therapy

  1. Develop a care plan for presenting patients from an osteopathic perspective

 

515 – 530 PM: Patient Consultations; Pharmacist Perspective with Dr. Shane Carmichael, PharmD

Integrate medical Cannabis as a complementary or alternative therapy

  1. Develop a care plan for presenting patients from a pharmacist perspective

530 PM – 6 PM: Case Discussion #2: Complex Patient Presentations 

Design safe and effective treatment regimens for complex patient presentations

  1. Formulate appropriate initial recommendations for cannabis-naïve and experienced patients
  2. Construct alternative recommendations for patients experiencing formulation-specific or cannabinoid-specific adverse reactions

>>> Conclusion of Day 1 Continuing Education accredited activities

6 PM – 7 PM:  Exhibitor Sponsored Cocktail Hour

7 PM – 9 PM:  Dinner  

 

SATURDAY, AUGUST 15, 2020 

7 AM – 8 AM: Breakfast  

8 AM – 845 AM: Special Populations: Pregnancy and Lactation with Dr. Laura Borgelt, PharmD  

Evaluate the use of medical Cannabis in special populations including pregnancy and lactation

  1. Explain the role of the ECS during prenatal and perinatal phases
  2. Interpret the risk of cannabis products for developing bodies
  3. Analyze the presence of cannabinoids in breast milk following maternal consumption

 

845 AM – 930 AM: Special Populations: Pediatrics with Dr. Bonni Goldstein, MD  

Evaluate the use of medical Cannabis in special populations including pediatrics and young adults  

  1. Identify potential pediatric conditions that could benefit from the use of medical Cannabis
  2. Compare the benefits and risks of phytocannabinoids; THC, CBD, CBG, CBN, and THCV in pediatric populations
  3. Construct initial dosing recommendations for pediatric patients with cancer, autism, pain, and epilepsy

 

930 AM – 10 AM: Special Populations: Geriatrics with Dr. Dustin Sulak, DO

Evaluate the use of medical Cannabis in special populations including geriatrics

  1. Summarize the risks of medical Cannabis in geriatric populations
  2. Develop dosing algorithms for cannabis-naïve elderly patients

 

10 AM – 1030 AM: Exhibitor Break  

 

1030 AM – 1130 AM: Psychiatric Considerations with TBD    

Explain the neuropsychiatric implications of Cannabis use in various populations

  1. Identify the association of neurocognitive impairment in adolescent versus adult populations
  2. Compare functional MRI (fMRI) scans in recreational and medical Cannabis users and the implications to prevent harm
  3. Summarize the findings of the National Academy of Sciences, Engineering, and Medicine related to the development of Cannabis-induced anxiety, depression, schizophrenia, and bipolar mania.

 

1130 AM – 1145 AM: Mindfulness Techniques with TBD 

 

1145 AM – 1230 PM:  Panel: Future of Cannabis Pharmacy Moderated by Dr. Jeff Lombardo, PharmD, BCOP with TBD

Interpret the future of Cannabis medicine and the role of the healthcare professional 

  1. Explain the current legal landscape and regulatory challenges of Cannabis across the United States and Canada
  2. Evlaute the public perception and role of cannabinoids in medical models across the globe
  3. Identify challenges to standardization of medical products across state/country lines
  4. Predict the future of Cannabis pharmacy and the implications for the role of the pharmacist

 

1230 PM – 1 PM: Patient Case #3: Special Populations

Design safe and effective palliative care regimens for special populations including pediatrics and geriatrics  

  1. Formulate appropriate initial recommendations for sensitive populations including pediatrics and geriatrics
  2. Construct alternative recommendations for patients experiencing formulation-specific or cannabinoid-specific adverse reactions

 

>>> Conclusion of Day 2 Continuing Education accredited activities

1 PM – 2 PM: Optional Focus Group Opportunities